Ceruloplasmin is an abundant c2-serum glycoprotein that contains 95% of the copper found in the plasma of vertebrate species. We report here on the identification of a genetic defect in the ceruloplasmin gene in a patient previously noted to have a total absence of circulating serum ceruloplasmin in association with late-onset retinal and basal ganglia degeneration. 
tion at amino acid 410, resulting in a frame-shift mutation and a truncated open reading frame. The validity of this mutation was confirmed by analysis of DNA from the patient's daughter, which revealed heterozygosity for this same 5-bp insertion. The presence of this mutation in conjunction with the clinical and pathologic findings demonstrates an essential role for ceruloplasmin in human biology and identifies aceruloplasminemia as an autosomal recessive disorder of iron metabolism. These findings support previous studies that identified ceruloplasmin as a ferroxidase and are remarkably consistent with recent studies on the essential role of a homologous copper oxidase in iron metabolism in yeast. The clinical and laboratory findings suggest that additional patients with movement disorders and nonclassical Wilson disease should be examined for ceruloplasmin gene mutations.
In 1948 Holmberg and Laurell (1) isolated an abundant copper-containing protein from pig serum that they termed ceruloplasmin or "the sky-blue protein." In this same year, the hepatolenticular degeneration of Wilson disease was found to be due to excess copper accumulation (2) . After these discoveries, the observation was made that the serum ceruloplasmin concentration is decreased in Wilson disease, thus providing a diagnostic test for this disorder (3) . Further clinical studies revealed the acute-phase nature of this protein and identified individuals with inherited differences in serum ceruloplasmin concentrations (4, 5) . Analysis of one such family identified this alteration as hereditary hypoceruloplasminemia and concluded that no clinical abnormalities were associated with changes in serum ceruloplasmin to 50% of normal (6) . The marked decrease in serum ceruloplasmin in Wilson disease is not a primary defect but the result of impaired copper trafficking into a common pool for biliary excretion and holoceruloplasmin biosynthesis. Consistent with this, the Wilson disease gene was recently cloned and encodes a putative copper-transporting ATPase presumably located within the secretory compartment of hepatocytes (7) (8) (9) .
Ceruloplasmin is a blue copper oxidase that is synthesized in hepatocytes and secreted as a holoprotein with six atoms of copper incorporated during biosynthesis (10) . Copper does not affect that rate of synthesis or secretion of apoceruloplasmin, but failure to incorporate copper during biosynthesis results in an unstable protein lacking oxidase activity (11) . Although the copper ligands in ceruloplasmin are unknown, physicochemical studies reveal the presence of a trinuclear copper cluster in the carboxyl-terminal domain essential for oxidase activity (12) . Amino acid sequencing of human ceruloplasmin was a tour de force, proving the single-chain structure of the protein and identifying triplicate repeat domains of 350 amino acids (13) . Subsequently homology was identified in these domains with clotting factors V and VIII (14) . Subsequent cloning of the human cDNA confirmed these sequence data and demonstrated the mechanisms of gene expression during the acute-phase response (15) (16) (17) (18) .
Despite years of investigation, the functional role of ceruloplasmin has not been clarified. A direct role in copper transport is unlikely, given kinetic data that indicate that the copper is turned over at the same rate as the protein (19) . In a series of biochemical investigations Osaki et al. (20) demonstrated ceruloplasmin ferroxidase activity, suggesting a role for ceruloplasmin in ferric iron uptake by transferrin. Consistent with this concept, the anemia that develops in copperdeficient animals is unresponsive to iron but is correctable by ceruloplasmin administration (21) . After the cloning of the Wilson disease gene, we have investigated a number of patients referred to us for molecular diagnosis with neurologic degeneration and low serum ceruloplasmin. In the course of this analysis we recognized that several of these patients did not have Wilson disease and have begun to reexamine the role of ceruloplasmin in human disease. In this study, we report the genetic analysis of one such patient originally identified in Hamamatsu, Japan, and reported as a case of familial apoceruloplasmin deficiency (22) .
MATERIALS AND METHODS
DNA Preparation and Analysis. DNA was isolated from peripheral blood and layered on Hypaque solution (Sigma) followed by centrifugation at 400 x g for 10 min. Leukocytes were removed from the buffy coat and lysed in hypotonic saline; DNA was then precipitated and purified as described (23 For additional analysis amplified fragments were isolated in DEAE paper and subcloned into the PCRII vector (Invitrogen) by T-tail cloning (24) . Individual colonies were isolated, and DNA was sequenced by the dideoxynucleotide chaintermination method (25) . For Southern blot analysis genomic DNA was digested with restriction endonuclease according to specifications (Promega), electrophoresed in 0.6% agarose gels, transferred to nylon Hybond-N (Amersham) membranes, and hybridized overnight at 42°C with a 32P-labeled cRNA antisense probe encoding human ceruloplasmin (17) . After hybridization, Southern blots were washed and exposed to film as described (24) . Ceruloplasmin concentration and oxidase activity in the sera were measured as described (10, 17) . Serum ceruloplasmin was analyzed by immunoblotting using a polyclonal antibody.
RESULTS
The index patient whose DNA is examined in this study is currently a 61-yr-old woman with retinal degeneration and blepharospasm for the past 10 yr. Since her original presentation, she has also developed cogwheel rigidity and dysarthria. Her younger sister, who was asymptomatic at the time of the original presentation despite undetectable ceruloplasmin, is currently 51 yr old and has had the recent onset of retinal degeneration and basal ganglia symptoms. In each case the absence of serum ceruloplasmin is associated with mild anemia, low serum iron, and elevated serum ferritin. Magnetic resonance imaging studies reveal prominently decreased signal intensity in the basal ganglia on T2 (transverse relaxation time)-weighted images, suggestive of significantly elevated content of iron in the brain (Y.T. and H.M., unpublished work). The daughter of the patient reported here is entirely asymptomatic and, as noted earlier, has a serum ceruloplasmin concentration that is 50% of normal, consistent with an obligate heterozygote. There is no history of consanguinity present in the family, and the number of affected members, as well as evaluation of the proband's offspring, suggest this as an autosomal recessive disorder. The clinical studies and details of iron and copper metabolism in the extended family will be presented elsewhere.
Genomic DNA was isolated from this 61-yr-old woman to determine directly whether a mutation in the ceruloplasmin gene might account for the decreased ceruloplasmin in the serum. Southern blot analysis of the isolated DNA using cDNA probes encompassing the entire ceruloplasmin-coding region revealed no fragment size differences between the patient's sample and normal control DNA (data not shown). To assess directly the relative size of each exon encoding the ceruloplasmin gene, we next performed PCR using the oligonucleotide primer pairs shown in Table 1 . Amplification primers corresponding to exon 19 were omitted, as it seemed less likely that a mutation in the 3' untranslated region would result in a lack of detectable ceruloplasmin. After analysis of all amplification products on polyacrylamide gels, an obvious size difference was observed in exon 7 amplified from the patient's DNA compared with controls ( Fig. 1, lanes 3 and 4) . The predicted size of this exon is 140 bp (see Table 1 (Fig.  1, lane 6) . To be certain that this finding reflected a unique genetic difference, genomic DNA was isolated from the patient's daughter and subjected to similar analysis. As can be seen in Fig. 1, although (Fig. 1, lanes 3-5) .
The results of the amplification of exon 7, including the evidence of heterozygosity in the daughter, strongly supported the idea that this exon contained an insertional mutation that might account for the aceruloplasminemia. To determine this possibility directly, the amplified exon 7 products from each of the samples shown in Fig. 1 were subcloned and sequenced. As can be seen in Fig. 2 family, as the sequence of exon 7 from the St. Louis patient with aceruloplasminemia was entirely normal (data not shown).
We next examined the effects of such an insertion on the open reading frame of ceruloplasmin. As shown in Fig. 3 the insertion results in a frame-shift at amino acid 411 that terminates 34 amino acids downstream, predicting a protein of 445 amino acids in contrast to the normal 1046-amino acid ceruloplasmin. Although we have termed this truncated protein ceruloplasmin Hamamatsu, the deletion of the carboxylterminal copper-containing trinuclear cluster would predict that were any protein translated, it would lack oxidase activity and be unstable in the plasma after secretion. The polyclonal antisera used in these studies is able to recognize determinants in the NH2 terminal domain, and thus the failure to detect a truncated protein in the plasma suggests impaired secretion or rapid turnover. These data are entirely consistent with the aceruloplasminemia observed.
DISCUSSION
The data presented here indicate that the clinical findings of abnormal iron metabolism and neurologic degeneration previously observed in this patient are the result of a mutation in the ceruloplasmin gene. The evidence of heterozygosity for this exon-7 mutation in the proband's daughter, the family pedigree, and the failure to detect any deletions in this region by Southern blotting of the patient's DNA support the concept that despite a lack of consanguinity in the family history, the patient reported here is homozygous for this particular mu- (26) obtained the first evidence of a role for copper in mammalian biochemistry. Engaged in studies to elucidate the cause of pernicious anemia, these investigators discovered serendipitously that the anemia that develops in rats fed cow's milk is responsive only to copper, leading to "the orthodox suggestion that the copper acts as a catalyzer for some reaction concerned in hemoglobin building" (26) . Subsequent studies in copperdeficient swine established that copper deficiency results in a disorder of iron storage and that ceruloplasmin administration could correct this situation (27) . Osaki Finally, some aspects of the clinical presentation of aceruloplasminemia deserve further discussion. Although the mechanisms of late-onset neurologic degeneration are not known, this delay in presentation is consistent with that observed in other degenerative diseases of the basal ganglia, such as Parkinson and Huntington diseases. This late onset is a potential mechanism for persistence of this recessive mutation in the population because symptoms appear after the onset of reproductive age. These issues highlight the potential importance of genetic screening, which despite the presence of multiple mutations may be possible because both the heterozygote and homozygote state can be detected by a simple assay for serum ceruloplasmin oxidase activity. The potential role for dietary manipulation to prevent or ameliorate this disease further emphasizes the need for early diagnosis, as does our recent finding of a symptomatic heterozygote who received prolonged iron therapy in childhood (Z.L.H., and J.D.G., unpublished work). This latter observation suggests an analogy to familial hypercholesterolemia, where dietary intervention can greatly affect phenotypic expression in the heterozygote state. Because patients with aceruloplasminemia will appear to have typical iron-deficiency anemia, the potential problem of misdirected iron therapy is apparent. Although the incidence of this disease is not known, in the past 4 mo since initiating this work, we have become aware of more than a dozen families in different parts of the world. Accepting the incidence observed in the original studies on hereditary hypoceruloplasminemia (now believed to be the heterozygote state), these observations and the clinical and laboratory presentations suggest that additional screening of patients with uncharacterized movement disorders or atypical Wilson disease is warranted. The potential role for treatment of such patients with ceruloplasmin is also clearly an issue for future study.
